Evidence map›Paper›PMID 17229710›Full record

ArticleJournal of virology2007

New way of regulating alternative splicing in retroviruses: the promoter makes a difference.

Jens Bohne, Axel Schambach, Daniela Zychlinski

Abstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jens BohneExperimental Hematology, Hannover Medical School, Carl-Neuberg-Strasse 1, OE 6960, D-30625 Hanover, Germany. bohne.jens@mh-hannover.de
Axel Schambach
Daniela Zychlinski

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing has been recognized as a major mechanism for creating proteomic diversity from a limited number of genes. However, not all determinants regulating this process have been characterized. Using subviral human immunodeficiency virus (HIV) env constructs we observed an enhanced splicing of the RNA when expression was under control of the cytomegalovirus (CMV) promoter instead of the HIV long terminal repeat (LTR). We extended these observations to LTR- or CMV-driven murine leukemia proviruses, suggesting that retroviral LTRs are adapted to inefficient alternative splicing at most sites in order to maintain balanced gene expression.

Indexed as

Alternative SplicingCytomegalovirusGene Products, tatHIVHIV Long Terminal RepeatLeukemia Virus, MurinePromoter Regions, GeneticRNA, Viraltat Gene Products, Human Immunodeficiency VirusViral Envelope ProteinsGene Products, tatRNA, Viraltat Gene Products, Human Immunodeficiency VirusViral Envelope Proteins

Identifiers

PMID17229710
PMCPMC1866029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.